Abstract 1037P
Background
Interleukin-12 (IL12) is a potent immunostimulatory cytokine that enhances T- and NK-cell-mediated anti-tumor immunity. The targeted delivery of IL12, by conjugation to the tumor-targeting antibody L19, increased the therapeutic index and showed a potent anti-tumor effect in mouse models. The L19 antibody binds to the alternatively spliced extra domain B (EDB) of fibronectin, an abundant component of the stroma of most solid tumors, which is undetectable in most healthy adult tissues. The promising preclinical results with EDB-targeted IL12 provided the motivation to study IL12-L19L19 in a phase I clinical trial.
Methods
Eligible patients (pts) have progressive metastatic solid cancers and transiently benefited from prior immune checkpoint inhibitors. The treatment consists of weekly intravenous administrations of IL12-L19L19 up to a maximum of eight infusions, followed by bi-weekly maintenance until disease progression, unacceptable toxicity, withdrawal of consent, or the investigator’s decision. During the Dose Escalation part, patients are sequentially assigned to 9 dose levels (0.1 μg/kg to 32 μg/kg). The Dose Escalation continues until the Dose Limiting Toxicity (DLT) rate reaches 33% in a cohort of 2 – 6 pts. Once the Recommended Dose (RD) is defined, 40 additional pts will be treated in the Dose Expansion part.
Results
A total of 14 pts (median age 62 years [37-72], 9 male, 5 female) have completed the DLT observation window in cohorts 1 – 5. The most common tumor types are NSCLC (4 pts) and melanoma (3 pts). One patient in cohort 3 (0.5 μg/kg) developed a DLT (G3 transient AST/ALT increase). None of the pts in cohorts 1 (0.1 μg/kg), 2 (0.25 μg/kg), 4 (1 μg/kg), and 5 (2 μg/kg) developed a DLT. The most common treatment-related adverse events (TRAEs) of any grade were fever (88%), fatigue (41%), and lymphocyte count decrease (41%). The most common CTCAE G3 TRAE was pyrexia (12%). 8 of 14 pts had Stable Disease, and one patient suffering from metastatic TNBC achieved a Partial Response at week 8. The Dose Escalation part of the trial is still ongoing.
Conclusions
Intravenous infusion with IL12-L19L19 treatment has been tolerated up to 2 μg/kg. The RD of IL12-L19L19 is still to be defined. Initial signs of activity have been observed.
Clinical trial identification
EudraCT 2019-000613-36, NCT04471987.
Editorial acknowledgement
Legal entity responsible for the study
Philogen S.p.A.
Funding
Philogen S.p.A.
Disclosure
W. Alsdorf: Financial Interests, Personal, Other, fees for congress participation: Janssen, Biontech; Financial Interests, Personal, Other, assistance in medical writing: Biontech. I. Colombo: Financial Interests, Personal, Expert Testimony: AstraZeneca, GSK; Financial Interests, Personal, Other, Travel grants: Tesaro, GSK; Financial Interests, Institutional, Expert Testimony: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Other, Travel Grants: AstraZeneca; Financial Interests, Personal, Other, travel grants: Janssen; Financial Interests, Personal, Full or part-time Employment, My husband was a Medtronic employee until 04.2020: Medtronic; Financial Interests, Personal, Full or part-time Employment, My husband is an employee since 02.2022: Medtronic; Financial Interests, Personal, Stocks/Shares: Medtronic; Financial Interests, Institutional, Invited Speaker: MSD, Bayer, Vivesto, Incyte, AstraZeneca; Non-Financial Interests, Leadership Role: Swiss Group for Clinical Cancer Research (SAKK). S. Dakhel: Financial Interests, Personal, Full or part-time Employment: Philochem AG. T. Hemmerle: Financial Interests, Personal, Full or part-time Employment: Philochem AG, Philogen S.p.A.. E. Puca: Financial Interests, Personal, Full or part-time Employment: Philochem AG; Financial Interests, Personal, Member of the Board of Directors: Philogen S.p.A.. C. Libbra: Financial Interests, Personal, Full or part-time Employment: Philogen S.p.A.. S. Mulatto: Financial Interests, Personal, Full or part-time Employment: Philogen S.p.A.. J.C. Mock: Financial Interests, Personal, Full or part-time Employment: Philogen S.p.A., Philochem AG. K. Lorizzo: Financial Interests, Personal, Full or part-time Employment: Philogen S.p.A.. D. Neri: Financial Interests, Personal, Member of the Board of Directors: Philochem AG, Philogen S.p.A.; Financial Interests, Personal, Full or part-time Employment: Philogen S.p.A., Philochem AG. A. Covelli: Financial Interests, Personal, Full or part-time Employment, CMO: Philogen S.p.A.; Financial Interests, Personal, Advisory Board, Scientific Advisory Board: Cellestia Biotech, Italfarmaco, Peptomyc. U. Lauer: Financial Interests, Personal, Other, Consultant: Boehringer Ingelheim, ViraTherapeutics; Financial Interests, Personal, Advisory Role: Novartis, Amgen, Bayer, Asgard Therapeutic. J.C. Hassel: Financial Interests, Personal, Invited Speaker: BMS, Novartis, sanofi, MSD, Sunpharma, Almirall, Roche, Amgen, GSK, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, Pierre Fabre, Sunpharma, GSK; Financial Interests, Institutional, Advisory Board: Novartis, BMS, Immunocore, Nektar, Philogen; Financial Interests, Institutional, Research Grant: BMS, Sunpharma; Financial Interests, Institutional, Invited Speaker: Philogen, BMS, Genentech, Immunocore, Immunocore, 4SC, Novartis, BioNTech, Idera, Iovance, Nektar, Pierre Fabre, Regeneraon, Sanofi; Non-Financial Interests, Leadership Role: DeCOG; Non-Financial Interests, Member: ASCO. A. Stathis: Financial Interests, Institutional, Expert Testimony: Bayer, Eli Lilly; Financial Interests, Institutional, Advisory Board: Janssen, Roche; Financial Interests, Institutional, Other, Travel grant: AstraZeneca; Financial Interests, Institutional, Invited Speaker: Pfizer, Merck MSD, Roche, Novartis, ADC Therapeutics, AbbVie, Bayer, Philogen, Cellestia, AstraZeneca, Incyte, Amgen, Loxo Oncology. W.M. Fiedler: Financial Interests, Other, Personal fees and non-financial support: AbbVie; Financial Interests, Research Grant: Amgen, Apis, Pfizer; Financial Interests, Other, personal fees and non-financial support: Amgen, Apis, Pfizer; Financial Interests, Other, personal fees: Jazz Pharmaceuticals, Celgene, Morphosys, Incyte, Stemline Therapeutics, Daiichi Sankyo, Servier; Financial Interests, Other, patent: Amgen; Financial Interests, Other, support for medical writing: Amgen, Pfizer, AbbVie. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Invited Speaker, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO. All other authors have declared no conflicts of interest.
Resources from the same session
1353P - Effect of TP53 co-mutation in non-small cell lung cancer (NSCLC) with driver mutations
Presenter: Jamie Feng
Session: Poster session 19
1354P - Beyond the common mutation: Examining chemotherapy success in uncommon EGFR mutations
Presenter: Chien-Chung Lin
Session: Poster session 19
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19